# US 11,440,882 B2 · Process for the preparation of dexmethyl phenidate hydrochloride

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,440,882 B2
- Document ID: US11440882B2
- Status: Granted
- Kind: B2
- Application number: 16/319,175
- Filed: 2017-07-17
- Published: 2021-12-02
- Granted: 2022-09-13
- Earliest claimed: 2016-07-18
- Assignees: Harman Finochem Limited
- Applicants: Harman Finochem Limited
- Inventors: Vijay Trimbak Kadam; Nareesh Saranapu; Santosh Uttamrao Chavan; Harpreet Singh Minhas; Gurpreet Singh Minhas
- Web page: https://patentgrep.com/patent/US11440882B2

## CPC

- C07D 211/34: with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed herein a process for the preparation of highly pure dexmethylphenidate hydrochloride (Formula-I) which comprises the steps of neutralization of dl-threomethylphenidate hydrochloride to dl-threo methylphenidate; subsequent resolution of dl-threo methylphenidate using amino acid or its derivatives as chiral resolution agent to yield dexmethylphenidate salt; hydrolysis of the salt and further conversion of dexmethylphenidate into its hydrochloride salt.

## Claims

### Claim 1

A process for the preparation of optically pure dexmethylphenidate hydrochloride of Formula-I,
comprising:
a) neutralizing dl-threo-methylphenidate hydrochloride with a base in the presence of an organic solvent to produce dl-threo-methylphenidate;
b) resolving the dl-threo-methylphenidate with a chiral amino acid or a derivative thereof in the presence of an alcohol or ketone solvent to obtain an amino acid salt of dexmethylphenidate, wherein the chiral amino acid is selected from the group consisting of valine, leucine, isoleucine, L-phenylalanine, glutamic acid, aspartic acid, and combinations thereof;
c) converting the amino acid salt of dexmethylphenidate into its free base in the presence of a base and an organic solvent; and
d) converting the free base of dexmethylphenidate obtained in step (c) into its hydrochloride salt.

### Claim 2 (depends on 1)

The process according to claim 1, wherein the neutralizing step comprises neutralizing dl-threo-methylphenidate hydrochloride with an aqueous base.

### Claim 3 (depends on 2)

The process according to claim 2, wherein the neutralizing step comprises neutralizing dl-threo-methylphenidate hydrochloride with aqueous sodium hydroxide or aqueous potassium hydroxide.

### Claim 4 (depends on 1)

The process according to claim 1, wherein the neutralizing step comprises neutralizing dl-threo-methylphenidate hydrochloride in the presence of an organic solvent selected from the group consisting of ethyl acetate, dichloroethane, dichloromethane, cyclohexane, heptane, toluene, and a mixture thereof.

### Claim 5 (depends on 1)

The process according to claim 1, wherein the neutralizing step comprises neutralizing dl-threo-methylphenidate hydrochloride in the presence of an organic ester solvent or an aromatic hydrocarbon solvent.

### Claim 6 (depends on 1)

The process according to claim 1, wherein the neutralizing step comprises neutralizing dl-threo-methylphenidate hydrochloride in the presence of an organic solvent selected from the group consisting of dichloromethane, cyclohexane, heptane, toluene, and a mixture thereof.

### Claim 7 (depends on 1)

The process according to claim 1, wherein the resolving step comprises resolving the dl-threo-methylphenidate in the presence of an alcohol or ketone solvent selected from the group consisting of methanol, ethanol, n-propanol, isopropanol, acetone, methyl ethyl ketone (MEK), methyl isobutyl ketone, and a mixture thereof.

### Claim 8 (depends on 1)

The process according to claim 1, wherein the step of converting the amino acid salt of dexmethylphenidate into its free base comprises:
converting the amino acid salt of dexmethylphenidate into its free base in the presence of an organic solvent selected from the group consisting of an ester solvent, a halogenated hydrocarbon solvent, and a mixture thereof.

### Claim 9 (depends on 8)

The process according to claim 8, wherein the step of converting the amino acid salt of dexmethylphenidate into its free base comprises:
converting the amino acid salt of dexmethylphenidate into its free base in the presence of an organic solvent selected from the group consisting of ethyl acetate, ethyl butyrate, ethyl lactate, butyl acetate, isopropyl acetate, isobutyl acetate, isoamyl acetate, dichloroethane, dichloromethane, and a mixture thereof.

### Claim 10 (depends on 1)

The process according to claim 1, wherein the step of converting the amino acid salt of dexmethylphenidate into its free base comprises:
converting the amino acid salt of dexmethylphenidate into its free base in the presence of an organic solvent selected from the group consisting of ethyl acetate, ethyl butyrate, ethyl lactate, butyl acetate, isopropyl acetate, isobutyl acetate, isoamyl acetate, dichloroethane, dichloromethane, cyclohexane, heptane, toluene, and a mixture thereof.

### Claim 11 (depends on 1)

The process according to claim 1, wherein the step of resolving the dl-threo-methylphenidate comprises resolving the dl-threo-methylphenidate with a derivative of a chiral amino acid;
wherein the derivative of the chiral amino acid is a methanesulfonyl derivative, a para-toluenesulfonyl derivative, an acetyl derivative, a benzenesulfonyl derivative, a para-nitrobenzenesulfonyl derivative, a para-chlorobenzenesulfonyl derivative, or a combination thereof.

### Claim 12 (depends on 1)

The process according to claim 1, wherein the step of resolving the dl-threo-methylphenidate comprises resolving the dl-threo-methylphenidate with a chiral amino acid or a derivative thereof;
wherein the chiral amino acid or the derivative thereof is selected from the group consisting of L-methanesulfonyl valine, N-paratoluenesulfonyl valine, L-acetyl valine, leucine, isoleucine, L-phenyl alanine, methanesulfonyl aspartic acid, methanesulfonyl glutamic acid, benzenesulfonyl aspartic acid, benzenesulfonyl glutamic acid, paratoluenesulfonyl aspartic acid, N-paratoluenesulfonyl (tosyl) glutamic acid, paranitrobenzenesulfonyl aspartic acid, paranitrobenzenesulfonyl glutamic acid, parachlorobenzenesulfonyl aspartic acid, parachlorobenzenesulfonyl glutamic acid, and a combination thereof.

### Claim 13 (depends on 1)

The process according to claim 1, wherein the dexmethylphenidate hydrochloride is produced with an optical purity of 97% to 99.9%.

### Claim 14 (depends on 11)

The process according to claim 11, wherein the dexmethylphenidate hydrochloride is produced with an optical purity of 99% to 99.9%.

### Claim 15 (depends on 12)

The process according to claim 12, wherein the dexmethylphenidate hydrochloride is produced with an optical purity of greater than 99.5% to 99.9%.
